SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors

The identification of novel oncogenic driver alterations and novel mechanisms of acquired resistance (AR) is the key for further development of personalized therapy. The current study investigates the potential role of YES1 amplification as a primary driver of tumorigenesis and of YES1/YAP1 amplific...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Hiroki, Kubota, Daisuke, Qiao, Huan, Jungbluth, Achim, Rekhtman, Natasha, Schoenfeld, Adam J., Yu, Helena A., Riely, Gregory J., Toyooka, Shinichi, Lovly, Christine M., Paik, Paul, Ladanyi, Marc, Fan, Pang-Dian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384924/
https://www.ncbi.nlm.nih.gov/pubmed/35952318
http://dx.doi.org/10.1200/PO.22.00088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384924/
https://www.ncbi.nlm.nih.gov/pubmed/35952318
http://dx.doi.org/10.1200/PO.22.00088

Ejemplares similares